Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... for the next line of drugs front ran the stock price. For example, in 2016 Lilly was trading 13 times the trailing 12 months ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Should you invest $1,000 in Eli Lilly right now? Stock Advisor analyst team just identified what ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...